Seattle biotech BrainChild Bio has raised $116 million to advance an experimental CAR T cell therapy for DIPG, a rare and ...

BrainChild Bio has raised $116 million in Series A funding to advance its CAR T cell therapies for central nervous system ...

Cloverleaf Bio Raises $33 Million Seed Financing to Advance Novel RNA-Based Cancer Therapeutics Oversubscribed round led by 4BIO Capital includes strategic investment from AbbVie Ventures, Lilly, and ...

Brain tumors develop within an organ that changes substantially with age. A new review in Ageing and Cancer Research & ...

Massive Bio, Inc., a global leader in AI-driven precision oncology and clinical trial matching, and PrecisCa, an oncology practice support platform offering evidence-based treatment guidance, clinical ...

BrainChild Bio’s lead asset BCB-276 is in pivotal development for diffuse intrinsic pontine glioma, a rare and fatal brain tumor that affects around 300 children in the U.S. every year.

BARCELONA, Spain--(BUSINESS WIRE)--Massive Bio, a global leader in artificial intelligence (AI) for cancer clinical trial enrollment, has announced the launch of Patient Connect, an innovative and ...

NORTH CHICAGO, IL, UNITED STATES, September 1, 2026 /EINPresswire.com/ — BLR Bio LLC announced new findings demonstrating the potential of its first in class, Yes-Associated Protein (YAP) ...

Innovate UK grant supports Athernal’s mission to intercept high-risk leukaemia before cancer developsFunding reflects growing confidence in cancer interception as an emerging therapeutic ...

Some breast cancer types are more likely than others to recur. Researchers have known this for more than a decade. But they have long wondered why. "How did those tumor types arise?" said Christina ...

This week, I address pushback I received on my Novartis-MorphoSys column. But first, a preview of the expected readout from Gritstone Bio’s neoantigen cancer vaccine study. Before the end of the ...